SOUTH SAN FRANCISCO, CA and TOKYO--(Marketwire - July 28, 2008) - CoMentis, Inc. and Astellas Pharma, Inc. announced today that the companies will present six abstracts related to CTS21166 (ASP1702), a beta-secretase inhibitor for the treatment of Alzheimer’s disease, at the 2008 International Conference on Alzheimer’s Disease (ICAD) in Chicago, July 26-31. CTS21166 (ASP1702) is the first of several highly selective, potent and orally active beta-secretase inhibitors being developed by CoMentis and Astellas.
